Over 50 million people in the world are living with dementia, as more people tend to live into the old age, the patient number is expected to be triple by 2050. Alzheimer’s disease (AD) is the most prevalence cause of dementia and accounts for two thirds of the cases. Until now, there is no treatment available to halt or reverse the underlying pathology of AD, only early diagnosis and treatment are the best chance to ameliorate the symptoms of this devastating disease.

MIND and Tech Ltd. is an innovative technology company developing novel nanoparticle-based tools for Medical Imaging and Nano Diagnostics. The company provides a cost-effective, simple, direct yet sensitive platform for early neurodegenerative diseases detection and diagnostics. Benefiting from the brand’s designed fluorophore, it is the first detection assay capable of measuring the subtle changes in the expression profile of disease associated biomarkers.

Their primary mission it to provide a solution for early Alzheimer’s disease diagnosis by developing an Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable (ASSURED) point-of-care tool for population-wide screening of Alzheimer’s disease and a magnetic resonance imaging (MRI) contrast agent for AD-associated biomarker imaging for Alzheimer’s disease diagnosis.

Detection of multiple circulating biomarkers including beta-amyloid, tau and p-tau being proved to be highly AD specific is the most reliable means for AD diagnosis. MIND and Tech Ltd. first-generation ultra-sensitive detection kit for beta-amyloid is now commercially available for laboratory use. The other two detection kits will be launched soon, and they believe that their detection kits can become one of the dispensable tools for population-wide screening of AD.

Please visit http://www.mind-and-tech.com/ for more details.